An educational guide
This information is for education and does not replace advice from a qualified healthcare professional.
By the A Weight Loss Tips editorial team · Last updated
No. Wegovy and Zepbound are FDA-approved for chronic weight management.[1][2] Ozempic and Mounjaro contain the same active ingredients but are approved for type 2 diabetes, not weight management.[3][4] Using them for weight loss alone is off-label.
“Diet pills” is a loose term that can mean prescription medicines, the one FDA-approved nonprescription option (orlistat 60 mg, sold as alli),[8] or dietary supplements. Supplements don’t need FDA approval for safety or effectiveness before they are sold.[11]
No. Each medicine has different approved uses, side effects and precautions. The right choice, if any, depends on a person’s health, other medicines, preferences and access, and is a decision to make with a clinician.
Each medicine has a short overview further down this page. Guides with a link have their own page; the others are on the way.
Semaglutide
A weekly semaglutide injection for adults with type 2 diabetes. It is not FDA-approved for weight management.
Read the full guide about OzempicSemaglutide
Semaglutide approved for chronic weight management, as a weekly injection or a daily tablet, plus other specific uses.
Detailed guide coming soon
Tirzepatide
A weekly tirzepatide injection for type 2 diabetes. It is not FDA-approved for weight management.
Detailed guide coming soon
Tirzepatide
Tirzepatide approved for chronic weight management in adults and for obstructive sleep apnea in adults with obesity.
Detailed guide coming soon
Several medicines and products
How prescription pills, the nonprescription option and dietary supplements differ in approval, evidence and safety.
Detailed guide coming soon
In-depth guides and comparisons, each on its own page.
Ozempic is a prescription diabetes medicine that is not FDA-approved for weight management. Learn how it works, its possible effects on weight, side effects, risks, and costs.
11 min read
There is no single Ozempic timeline. Blood sugar, A1C, appetite, and weight change on different schedules. Learn the checkpoints and how to review progress.
10 min read
Nausea, vomiting, diarrhea, stomach pain, and constipation are the most common Ozempic side effects. Learn the warning signs that need prompt or emergency care.
9 min read
Ozempic and Wegovy both contain semaglutide, but their approved uses, formulations, and dosing differ. Compare them side by side and learn why they are not interchangeable.
9 min read
Ozempic contains semaglutide and Mounjaro contains tirzepatide. Compare their approved uses, what head-to-head studies show, side effects, and why they are not interchangeable.
9 min read
Ozempic is not FDA-approved for weight management, so prescribing it for weight loss without diabetes is off-label. Learn what that means, what research shows, and what to ask.
10 min read
There is no single Ozempic meal plan. Learn how to build balanced meals, include protein and fiber, stay hydrated, and eat when you feel nauseated.
10 min read
Limited weight change on Ozempic doesn't mean the medicine isn't working or that you've failed. Explore possible reasons, what to track, and what to discuss with your doctor.
9 min read
Stopping Ozempic can bring appetite changes, weight regain, and blood sugar changes. Learn what research shows, why there's no standard taper, and how to plan follow-up.
10 min read
List prices, self-pay offers, insured costs and copay savings are different numbers. Learn what affects your Ozempic cost and how to check your actual price.
10 min read
The table summarizes U.S. approved uses and forms. It is not a ranking, and it doesn’t compare how much weight people lose, because results from separate trials can’t be compared directly.
Active ingredient
Semaglutide
Relevant U.S. approved use
Type 2 diabetes, including lowering certain heart and kidney risks.[3] Not approved for weight management.
Form
Weekly injection (a separate tablet version is for type 2 diabetes)[6]
Key distinction
Same ingredient as Wegovy, but different approved uses and doses
Active ingredient
Semaglutide
Relevant U.S. approved use
Chronic weight management; lowering heart attack and stroke risk in some adults; a liver condition (MASH) for the injection[1]
Form
Weekly injection or daily tablet[1]
Key distinction
The injection is also approved for ages 12 and up; the tablet is for adults[1]
Active ingredient
Tirzepatide
Relevant U.S. approved use
Type 2 diabetes, including lowering heart risks in some adults.[4] Not approved for weight management.
Form
Weekly injection[4]
Key distinction
Same ingredient as Zepbound, but different approved uses
Active ingredient
Tirzepatide
Relevant U.S. approved use
Chronic weight management; obstructive sleep apnea in adults with obesity[2]
Form
Weekly injection (pen or vial)[2]
Key distinction
Acts on two hormone receptors (GIP and GLP-1); adults only[2]
Active ingredient
Varies, e.g. semaglutide tablets, orforglipron, orlistat, phentermine-based and naltrexone/bupropion products
Relevant U.S. approved use
Form
By mouth; dosing rules differ
Key distinction
Different medicines with different mechanisms, uses and risks
| Brand or category | Active ingredient | Relevant U.S. approved use | Form | Key distinction |
|---|---|---|---|---|
| Ozempic | Semaglutide | Type 2 diabetes, including lowering certain heart and kidney risks.[3] Not approved for weight management. | Weekly injection (a separate tablet version is for type 2 diabetes)[6] | Same ingredient as Wegovy, but different approved uses and doses |
| Wegovy | Semaglutide | Chronic weight management; lowering heart attack and stroke risk in some adults; a liver condition (MASH) for the injection[1] | Weekly injection or daily tablet[1] | The injection is also approved for ages 12 and up; the tablet is for adults[1] |
| Mounjaro | Tirzepatide | Type 2 diabetes, including lowering heart risks in some adults.[4] Not approved for weight management. | Weekly injection[4] | Same ingredient as Zepbound, but different approved uses |
| Zepbound | Tirzepatide | Chronic weight management; obstructive sleep apnea in adults with obesity[2] | Weekly injection (pen or vial)[2] | Acts on two hormone receptors (GIP and GLP-1); adults only[2] |
| Oral weight-management medicines | Varies, e.g. semaglutide tablets, orforglipron, orlistat, phentermine-based and naltrexone/bupropion products | Varies by medicine[1][5][7] | By mouth; dosing rules differ | Different medicines with different mechanisms, uses and risks |
Oral weight-management medicines are a category, not a single drug. Wegovy tablets and Foundayo work on the GLP-1 pathway, while older pills work in other ways and some are meant only for short-term use.[1][5][7][14]
Same active ingredient doesn’t mean interchangeable: brands can differ in approved uses, doses and devices.
Appetite isn’t only about willpower. Hormones released by the gut after eating send signals to the brain that affect hunger and fullness. Several newer medicines work by acting on these signals.[7]
Semaglutide (Ozempic, Wegovy) and orforglipron (Foundayo) are GLP-1 receptor agonists. They copy the action of GLP-1, a gut hormone that acts on brain areas that control appetite and food intake.[5][7]
Tirzepatide (Mounjaro, Zepbound) activates receptors for two gut hormones, GIP and GLP-1, which helps reduce appetite and food intake.[2][7]
None of these medicines simply “burns fat.” Practical habits, like building a balanced plate, walking regularly and getting enough sleep, remain part of the plan.
Semaglutide and tirzepatide are each sold under two brand names. The brands share an active ingredient but are approved for different purposes.
Ozempic is a once-weekly semaglutide injection for adults with type 2 diabetes. It is approved to improve blood sugar along with diet and exercise, to lower the risk of major heart events in adults with type 2 diabetes and heart disease, and to lower certain kidney and heart risks in adults with type 2 diabetes and chronic kidney disease.[3]
It appears in weight discussions because it contains the same active ingredient as Wegovy. However, Ozempic is not FDA-approved for weight management, so prescribing it for weight loss alone is off-label.[3] Read more about Ozempic for weight loss without diabetes. Ozempic tablets also exist for type 2 diabetes. They share a label with Rybelsus tablets, and the two can’t be swapped milligram for milligram.[6] Read our full Ozempic guide for more detail.
Wegovy is semaglutide approved, with diet and physical activity, to reduce excess body weight and keep it off long term in adults with obesity, or with overweight and at least one weight-related condition. It is also approved to lower the risk of heart attack, stroke and cardiovascular death in adults with heart disease and obesity or overweight.[1]
Wegovy comes as a weekly injection or a once-daily tablet. The injection is also approved for adolescents 12 and older with obesity and for a liver condition called MASH with moderate to advanced scarring; the tablet is for adults only and must be taken on an empty stomach with a small amount of water.[1] The label also includes a higher weekly injection dose (Wegovy HD) for some adults.[1]
Mounjaro is a once-weekly tirzepatide injection approved to improve blood sugar in adults and children 10 and older with type 2 diabetes, and to lower the risk of major heart events in some adults with type 2 diabetes.[4]
It comes up in weight discussions because it shares its active ingredient with Zepbound, but Mounjaro itself is not FDA-approved for weight management.[4] See our Ozempic vs. Mounjaro comparison for how the two diabetes medicines differ.
Zepbound is tirzepatide approved, with diet and physical activity, to reduce excess body weight and maintain it long term in adults with obesity, or with overweight and at least one weight-related condition. It is also approved for moderate to severe obstructive sleep apnea in adults with obesity.[2]
It is a weekly injection, available as pens or vials, for adults only.[2]
“Diet pills” is a broad marketing and search term that covers three very different groups: prescription medicines, one approved nonprescription product, and supplements the FDA hasn’t reviewed for safety or effectiveness.
These need a prescription and come with FDA-approved labeling. Examples include:
Orlistat 60 mg, sold as alli, is the only FDA-approved over-the-counter weight loss aid. It works by preventing the body from absorbing some of the fat you eat. Its label warns of rare liver injury and, since 2026, of kidney stones and kidney injury.[8]
Being available without a prescription doesn’t make a product right for you. Ask a pharmacist or clinician whether it fits your health and other medicines.
Supplements are regulated differently from drugs. The FDA does not approve dietary supplements for safety and effectiveness before they are sold,[11] and none is equivalent to a prescription weight loss medicine. “Natural” on a label doesn’t mean safe.
Clinicians generally consider weight management medicines for adults with a body mass index (BMI) of 30 or higher, or 27 or higher with a weight-related health problem such as high blood pressure or type 2 diabetes.[7] That is a starting point, not a prescribing decision. Each medicine has its own approved ages and criteria, and the assessment usually looks at:
Weight-related health conditions
Medical history, including any history of pancreatitis, thyroid cancer or gallbladder problems
Other medicines and supplements
Approaches already tried
Age and the product’s specific eligibility criteria
Pregnancy, breastfeeding or plans to become pregnant
Personal risks, preferences and ability to keep up with treatment
You can use our BMI calculator as a screening reference, but BMI alone can’t tell whether a medicine is right for you. This page doesn’t offer a quiz or recommend a medication; that conversation belongs with a clinician who knows your health.
Side effects and warnings differ by medicine, so this is an overview, not a complete safety list. Read the official prescribing information and patient medication guide for any medicine you’re considering, linked in the sources below.
With semaglutide and tirzepatide, the most common side effects are digestive: nausea, diarrhea, vomiting, constipation and stomach pain.[1][2][3] Doses are usually increased gradually, partly to help with these effects.[1][2]
Other medicines have different profiles. Orlistat’s effects relate to the fat it blocks,[8] and naltrexone/bupropion carries a boxed warning about suicidal thoughts and behaviors.[13]
Labels for semaglutide, tirzepatide and orforglipron carry a boxed warning about thyroid C-cell tumors seen in rodents, and they should not be used by people with a personal or family history of medullary thyroid cancer or MEN 2.[1][2][5] Other warnings include pancreatitis, gallbladder problems, low blood sugar when combined with insulin or sulfonylureas, kidney problems linked to dehydration, and a risk of inhaling stomach contents during anesthesia or deep sedation.[1][2]
In 2026, the FDA asked for a suicidal thoughts warning to be removed from the labels of GLP-1 weight-management medicines after finding no increased risk.[12] Anyone with new or worsening depression or thoughts of self-harm should still contact a clinician promptly.
Pregnancy or plans to become pregnant: Wegovy should be stopped at least 2 months before a planned pregnancy, and Zepbound should be stopped when a pregnancy is recognized.[1][2]
Birth control pills: tirzepatide and orforglipron can make oral contraceptives less effective for a period after starting and after each dose increase.[2][5]
Diabetes medicines, a history of diabetic eye disease, or other prescription medicines[1][2]
Coverage depends on the specific product, what it’s prescribed for, your plan and whether prior authorization is required. A plan may cover a medicine for type 2 diabetes but not for weight management, or cover one brand and not another.
The list price, a manufacturer’s cash-pay offer and what you actually pay with insurance are three different numbers. Manufacturers run self-pay programs, such as NovoCare Pharmacy and LillyDirect, but they require a prescription and have eligibility terms. Prices and coverage rules change often, so check current details directly.
Is this product covered for my diagnosis?
Is prior authorization required?
Are there treatment prerequisites, such as trying other options first?
What will my out-of-pocket cost be?
What are the renewal requirements?
For Ozempic specifically, see Ozempic cost, insurance coverage and savings options.
These short comparisons answer the most common questions. Each brand’s overview above has more detail.
Same ingredient, different purpose: Ozempic treats type 2 diabetes, while Wegovy is approved for weight management and comes as an injection or tablet.[1][3] Doses and devices differ, so they aren’t interchangeable. Read the full Ozempic vs. Wegovy comparison.
Same ingredient, different purpose: Mounjaro treats type 2 diabetes, while Zepbound is approved for weight management and sleep apnea in adults with obesity.[2][4]
These have different active ingredients. Zepbound (tirzepatide) acts on GIP and GLP-1 receptors; Wegovy (semaglutide) acts on GLP-1 receptors.[1][2] Both are approved for chronic weight management, but their other approved uses, forms and age ranges differ. Results from their separate trials can’t be compared directly because the people studied, doses and timeframes differ.
Pills avoid needles but are usually taken every day, and some have strict rules about food, water and timing.[1][5] Weekly injections need fewer doses. “Pill” covers several very different medicines, so compare specific products rather than the form alone.
Bring these questions to your appointment to make the conversation more useful.
Is medication appropriate for my health situation?
Is the proposed use approved or off-label?
What benefits are realistic for me?
What side effects and interactions should I understand?
How will treatment be monitored?
What happens if I stop treatment?
How will cost and coverage affect treatment?
What nutrition and activity support would help?
Yes, for many people. NIDDK notes that people will probably regain some weight after stopping.[7] In two trials, adults who switched from semaglutide or tirzepatide to a placebo regained a substantial part of the weight they had lost.[15][16] Talk with your clinician before stopping, and see our tips on maintaining weight loss.
Sometimes. It depends on the product, the reason it’s prescribed, your plan and prior authorization rules. Ask your insurer the questions in the costs and coverage section above.
FDA label via DailyMed (NLM) — Wegovy (semaglutide) injection and tablets — Prescribing Information and Medication Guide. Checked Oct 20, 2026.
FDA label via DailyMed (NLM) — Zepbound (tirzepatide) injection — Prescribing Information and Medication Guide. Checked Oct 20, 2026.
FDA label via DailyMed (NLM) — Ozempic (semaglutide) injection — Prescribing Information and Medication Guide. Checked Oct 20, 2026.
FDA label via DailyMed (NLM) — Mounjaro (tirzepatide) injection — Prescribing Information and Medication Guide. Checked Oct 20, 2026.
FDA label via DailyMed (NLM) — Foundayo (orforglipron) tablets — Prescribing Information. Checked Oct 20, 2026.
FDA label via DailyMed (NLM) — Rybelsus and Ozempic (semaglutide) tablets — Prescribing Information. Checked Oct 20, 2026.
NIDDK (NIH) — Prescription Medications to Treat Overweight & Obesity. Checked Oct 20, 2026.
U.S. Food and Drug Administration — FDA approves labeling changes for over-the-counter weight loss drug alli (orlistat) to warn of risk of kidney injury. Checked Oct 20, 2026.
U.S. Food and Drug Administration — FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Checked Oct 20, 2026.
U.S. Food and Drug Administration — Avoiding Products Contaminated with Hidden Ingredients. Checked Oct 20, 2026.
U.S. Food and Drug Administration — Information for Consumers on Using Dietary Supplements. Checked Oct 20, 2026.
U.S. Food and Drug Administration — FDA requests removal of suicidal behavior and ideation warning from GLP-1 receptor agonist medications. Checked Oct 20, 2026.
FDA label via DailyMed (NLM) — Contrave (naltrexone/bupropion) extended-release tablets — Prescribing Information. Checked Oct 20, 2026.
FDA label via DailyMed (NLM) — Lomaira (phentermine) tablets — Prescribing Information. Checked Oct 20, 2026.
JAMA (2021), via PubMed — Rubino et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). Checked Oct 20, 2026.
JAMA (2024), via PubMed — Aronne et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). Checked Oct 20, 2026.
Numbered markers in the text link to these sources. Linking to a source doesn’t mean it endorses this site. Written by the A Weight Loss Tips editorial team. This page has not been medically reviewed.
Build a healthy weight loss approach around flexible routines, enjoyable meals, support, and habits you can adapt over the long term.
3 min read
Learn how to maintain weight loss with flexible routines, useful check-ins, support, and a plan for changes in everyday life.
2 min read
Learn a flexible way to build a balanced plate with familiar foods, practical examples, and room for your preferences and needs.
2 min read
Explore walking for weight loss through a flexible beginner routine, realistic expectations, and ways to make activity fit your schedule.
3 min read